Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (3980)	11/10/2015 12:14:20 AM
From: mulanoon2007	Read Replies (1) \| Respond to of 4474

Other TKIs that inhibit FGFR, PDGFR and VEGFR in clinical development for advanced NSCLC include: pazopanib, for pts with VEGFR or PDGFR mutations (NCT02193152, recruiting). nintedanib, for pts with VEGFR, PDGFR and FGFR mutations (NCT02299141, recruiting). Both squamous and adeno. Earlier efforts with anti-VEGFR antibodies in pts with squamous cell NSCLC (& not selected by molecular lesion) apparently found a high risk of lung hemorrhage and were quickly put out to pasture.